See more : CreditRiskMonitor.com, Inc. (CRMZ) Income Statement Analysis – Financial Results
Complete financial analysis of Anebulo Pharmaceuticals, Inc. (ANEB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anebulo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Iconic Sports Acquisition Corp. (ICNC) Income Statement Analysis – Financial Results
- Peijia Medical Limited (9996.HK) Income Statement Analysis – Financial Results
- 4C Group AB (publ) (4C.ST) Income Statement Analysis – Financial Results
- Roto-Gro International Limited (RGI.AX) Income Statement Analysis – Financial Results
- Baota Industry Co., Ltd. (000595.SZ) Income Statement Analysis – Financial Results
Anebulo Pharmaceuticals, Inc. (ANEB)
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.55M | 5.60M | 2.96M | 2.27M | 150.00K |
| General & Administrative | 4.76M | 6.18M | 3.87M | 1.34M | 140.11K |
| Selling & Marketing | 4.80K | 0.00 | 0.00 | 0.00 | 23.21K |
| SG&A | 4.76M | 6.18M | 3.87M | 1.34M | 23.35K |
| Other Expenses | 0.00 | -41.15K | -1.78K | -1.34K | 0.00 |
| Operating Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Cost & Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Interest Income | 97.79K | 92.41K | 7.33K | 1.02K | 7.72 |
| Interest Expense | 0.00 | 0.00 | 7.33K | 11.77K | 1.29K |
| Depreciation & Amortization | 258.28K | 11.78M | 6.83M | 3.61M | 1.04M |
| EBITDA | -8.05M | -11.78M | 5.56K | -30.24M | -173.35K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -11.78M | -6.83M | -3.61M | -173.35K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 107.05K | 51.26K | 5.56K | -26.64M | -1.29K |
| Income Before Tax | -8.20M | -11.73M | -6.83M | -30.25M | -174.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -104.19K | -12.89K | 10.75K | -1.04K |
| Net Income | -8.20M | -11.73M | -6.81M | -30.26M | -174.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| EPS Diluted | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Weighted Avg Shares Out | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
| Weighted Avg Shares Out (Dil) | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.
Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development
BOSTON--(BUSINESS WIRE)--Galehead Development, LLC (“Galehead”) and Rivian Automotive, LLC (“Rivian”) have entered into an agreement to collaborate on the development of renewable energy resources tailored to Rivian's locational and environmental priorities. Galehead will develop solar projects with specific consideration for...
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for...
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates.
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates.
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as...
Anebulo Pharmaceuticals Announces New CEO
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces New CEO.
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended...
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced that it will be giving an investor presentation at...
Source: https://incomestatements.info
Category: Stock Reports